ClinicalTrials.gg
Not yet recruitingNCT07370506Updated Jan 29, 2026

Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients

A Phase 1/2 interventional study of Telmisartan and Doxorubicin (DOX) in Breast Cancer and Doxorubicin Induced Cardiomyopathy, sponsored by Tanta University. Not yet recruiting at 1 site in Egypt. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-29.

Sponsored by Tanta University · Phase 1/2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Breast Neoplasms by Tanta University — 4 open to participants now, 4 under way, 1 of them phase 3. Breast Neoplasms · Tanta University.

Planned enrollment
13th of 14
36 · median 48
Started
2026
with 1 other
Phase 1/2
Only one
of the 14
Registered
13th of 14
by date

Among the 14 studies in Breast Neoplasms by Tanta University, this one is the 13th largest by planned enrollment, is one of 2 that started in 2026, is the only one in phase 1/2, and was the 13th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 14 studies in Breast Neoplasms by Tanta University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Breast Neoplasms by Tanta University, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy and safety of telmisartan as a cardioprotective agent in patients receiving doxorubicin-based chemotherapy, with the goal of reducing treatment-associated cardiotoxicity, optimizing therapeutic outcomes, and facilitating the safer administration of anthracycline regimens.

Read the detailed description

Doxorubicin remains one of the most effective chemotherapeutic agents for the treatment of a wide range of solid tumors and hematological malignancies. However, its clinical use is limited by dose-dependent cardiotoxicity, which may manifest as subclinical myocardial injury, left ventricular dysfunction, and progression to heart failure. The mechanisms underlying doxorubicin-induced cardiotoxicity are multifactorial, with oxidative stress recognized as a central pathway contributing to reactive oxygen species (ROS) generation, mitochondrial dysfunction, and cardiomyocyte injury. These effects highlight the need for strategies to reduce cardiovascular complications associated with doxorubicin therapy without compromising anticancer efficacy.

Telmisartan, an angiotensin II type 1 receptor blocker (ARB), has demonstrated pharmacological effects beyond blood pressure control. Preclinical studies suggest that telmisartan may reduce oxidative stress, improve endothelial function, and preserve mitochondrial integrity, partly through modulation of peroxisome proliferator-activated receptor gamma (PPAR-γ) pathways. These effects may contribute to attenuation of cardiac remodeling and myocardial injury. Despite these observations, clinical evidence evaluating telmisartan for the prevention of doxorubicin-induced cardiotoxicity remains limited and inconclusive. Recent in vitro findings also indicate that telmisartan may enhance doxorubicin-induced apoptosis and cytotoxic efficacy in cancer cell lines. These findings raise the possibility that telmisartan could exert both cardioprotective and chemosensitizing effects.

Considering this evidence gap, the present study is designed to investigate the cardioprotective role of telmisartan in patients undergoing doxorubicin-based chemotherapy.

03

Conditions studied

  • Breast Cancer
  • Doxorubicin Induced Cardiomyopathy

Browse trials for

Keywords

  • Telmisartan
  • Anthracycline Cardiotoxicity
  • Troponin
  • NT-proBNP
  • Cardioprotection
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients with breast cancer.
  • Age ≥18 \& ≤ 65 years.
  • Newly diagnosed, chemotherapy-naïve patients.
  • Baseline echocardiogram showing (LVEF) ≥55%.

Exclusion criteria

Exclusion Criteria:

  • Presence of to telmisartan.
  • History of cardiovascular disease (e.g., congestive heart failure, ischemic heart disease, arrhythmia).
  • Patients with any chronic liver or renal dysfunction; inflammatory diseases; disease; acute cardiovascular events, eating disorders (anorexia, bulimia) or gastrointestinal disorders.
  • Baseline blood pressure ≥ 160/100 mmHg
  • Current or prior use of ARBs/ACE inhibitors
  • Current participation in another clinical trial within the past 30 days.
  • Pregnant or breastfeeding women.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Telmisartan Group

    Participants receiving telmisartan in addition to standard doxorubicin-based chemotherapy.

    Drug: Telmisartan · Drug: Doxorubicin (DOX)

  • Active comparator
    Control Group

    Participants receiving standard doxorubicin-based chemotherapy without telmisartan.

    Drug: Doxorubicin (DOX)

Interventions

  • Telmisartan administered orally once daily as cardioprotective therapy during doxorubicin-based chemotherapy.

  • DrugDoxorubicinStudies of DoxorubicinDoxorubicin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Standard doxorubicin-based chemotherapy according to institutional protocol.

06

What researchers measure

Primary outcomes

  1. Change in Left Ventricular Ejection Fraction (LVEF)

    The primary outcome is the absolute change in left ventricular ejection fraction (LVEF) from baseline to the end of doxorubicin-based chemotherapy, assessed by echocardiography.

    Time frame: Baseline to end of chemotherapy (approximately 12-18 weeks)

Secondary outcomes

  1. Change in High-Sensitivity Cardiac Troponin T (hs-cTnT) Levels

    Measurement of serum hs-cTnT at baseline and at the end of doxorubicin-based chemotherapy to assess myocardial injury and cardiac stress in patients receiving telmisartan or standard care.

    Time frame: Baseline (pre-chemotherapy) to end of chemotherapy (approximately 12-18 weeks)

  2. Change in N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) Levels

    Measurement of serum NT-proBNP at baseline and at the end of doxorubicin-based chemotherapy. Any increase from baseline indicates early ventricular strain or subclinical heart failure in patients receiving telmisartan or standard care.

    Time frame: Baseline to end of chemotherapy (approximately 12-18 weeks)

07

Study locations

1 site
08

References and documents

Publications

  • Seino Y, Takahashi H, Fukumoto H, Utsumi K, Hirai Y. Cardiovascular manifestations of Fabry disease and the novel therapeutic strategies. J Nippon Med Sch. 2005 Oct;72(5):254-61. doi: 10.1272/jnms.72.254. PubMed 16247224 ↗
  • Taniguchi N. From the gamma-glutamyl cycle to the glycan cycle: a road with many turns and pleasant surprises. J Biol Chem. 2009 Dec 11;284(50):34469-78. doi: 10.1074/jbc.X109.023150. Epub 2009 Oct 19. No abstract available. PubMed 19840938 ↗
  • Arciuli J, Simpson IC. Statistical learning is lasting and consistent over time. Neurosci Lett. 2012 May 31;517(2):133-5. doi: 10.1016/j.neulet.2012.04.045. Epub 2012 Apr 25. PubMed 22561650 ↗
  • Simeunovic B, Strbenc M, Bavdek SV. Position and histological structure of the testes in the brown hare (Lepus europaeus) during seasonal regression and recrudescence. Anat Histol Embryol. 2000 Apr;29(2):73-82. doi: 10.1046/j.1439-0264.2000.00233.x. PubMed 10932383 ↗
  • Banegas JR, Segura J, Ruilope LM, Luque M, Garcia-Robles R, Campo C, Rodriguez-Artalejo F, Tamargo J; CLUE Study Group Investigators. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension. 2004 Jun;43(6):1338-44. doi: 10.1161/01.HYP.0000127424.59774.84. Epub 2004 Apr 26. PubMed 15117908 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Jan 2027, 11 months later.

Of 167 non-industry phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 95. This study's planned 11 months is below that.

Counting every sponsor, half of 331 studies reached it within 62 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2026
First posted
Jan 27, 2026
StartEst.
Feb 2026
Primary completionEst.
Jan 2027
CompletionEst.
Feb 2027
Last update
Jan 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07370506
Lead sponsor
Tanta University
Responsible party
Mennatullah Galal Ahmed Barakat (Teaching Assistant (Demonstrator) of Clinical Pharmacy, Tanta University) — Principal investigator
First posted
Jan 27, 2026
Start date
Feb 2026 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Jan 29, 2026

Study contacts

Menna Ahmed
Contact
mennagalal822@gmail.com
+20 1000854864

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telmisartan

Start the discussion